anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Cerebrovascular diseases in Sicily have led to high mortality and healthcare challenges, with a notable gap between healthcare demand and supply. The mobility of patients seeking care, both within and outside Sicily, has economic and organizational impacts on the healthcare system. The Hub and Spoke model implemented by the IRCCS Centro Neurolesi "Bonino-Pulejo" of Messina aims to distribute advanced neurorehabilitation services throughout Sicily, potentially reducing health mobility and improving service accessibility.
METHODS: The evaluation was based on calculating hospitalization rates, examining patient mobility across Sicilian provinces, and assessing the financial implications of neurorehabilitation admissions. Data from 2016 to 2018, covering the period before and after the implementation of the Hub and Spoke network, were analyzed to understand the changes brought about by this model.
RESULTS: The analysis revealed a significant increase in hospitalization rates for neurorehabilitation in the Sicilian provinces where spokes were established. This increase coincided with a marked decrease in interregional health mobility, indicating that patients were able to receive high-quality care closer to their residences. Furthermore, there was a decrease in both intra-regional and inter-regional escape rates in provinces within the Hub and Spoke network, demonstrating the network's efficacy in improving accessibility and quality of healthcare services.
DISCUSSION: The implementation of the Hub and Spoke network substantially improved neurorehabilitation healthcare in Sicily, enhancing both accessibility and quality of care for patients. The network's establishment led to a more efficient utilization of healthcare resources and balanced distribution of services. These advancements are vital steps toward equitable and effective healthcare delivery in Sicily.
FIELD: microbiology. SUBSTANCE: strain Neisseria meningitidis 356/4 (Collection GISK N 224) is selected from the strain N. meningitidis 356 (GISK) isolated from the patient cerebrospinal fluid followed by cloning and selection of variant exhibiting high and stable adhesive activity. Strain is gram-negative and 40% microbe cells form fimbrias. On the solid nutrient medium with 2% Hottinger agar with addition of 20% inactivated equine serum and 0.5% glucose the yield of biomass is 12 billion/ml for 18-20 h culturing. Strain ferments glucose and maltose with acid formation but does not ferment sucrose, levulose and lactose. Strain belongs to serogroup A, sticks to human erythrocytes and epitheliocytes of mucous. Adhesion index is 56 ± 17. EFFECT: bacterial strain indicated above. 2 tbl
Tertiary lymphoid structures (TLSs) are associated with enhanced immunity in tumors. However, their formation and functions in colorectal cancer liver metastasis (CRLM) remain unclear. Here, we reveal that intra- and peri-tumor mature TLSs (TLS+) are associated with improved clinical outcomes than TLS- tumors. Using single-cell-RNA-sequencing and spatial-enhanced-resolution-omics-sequencing (Stereo-seq), we reveal that TLS+ tumors are enriched with IgG+ plasma cells (PCs), while TLS- tumors are characterized with IgA+ PCs. By generating TLS-associated PC-derived monoclonal antibodies in vitro, we show that TLS-PCs secrete tumor-targeting antibodies. As the proof-of-concept, we demonstrate the anti-tumor activities of TLS-PC-mAb6 antibody in humanized mouse model of colorectal cancer. We identify a fibroblast lineage secreting CCL19 that facilitates lymphocyte trafficking to TLSs. CCL19 treatment promotes TLS neogenesis and prevents tumor growth in mice. Our data uncover the central role of CCL19+ fibroblasts in TLS formation, which in turn generates therapeutic antibodies to restrict CRLM.
OBJECTIVE: One of the difficulties in developing a novel drug for patients with amyotrophic lateral sclerosis (ALS) is the significant variation in the clinical course. To control this variation, a 12-week run-in period is used in some clinical trials. Based on the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) change during the run-in period, only moderate progressors are selected in some clinical trials. Some reports showed that the ALSFRS-R progression rate was associated with survival. However, it is unclear whether the ALSFRS-R change in the run-in period is a useful prognostic factor of the ALSFRS-R change from baseline. In addition, we explore the inclusion criteria that could control the variability in ALS-function progression without setting a run-in period.
METHODS: We utilized the Japanese and US ALS registry databases (JaCALS and PRO-ACT). Patients were classified into three populations (rapid, moderate, and slow progressors) based on the ALSFRS-R change prior to baseline. We also classified patients into three prognostic populations based on the ALSFRS-R change from baseline. We confirmed whether each of the three populations were matched with their respective three prognostic populations.
RESULTS: Our data showed that the three groups classified by the ALSFRS-R change during the 12 weeks prior to baseline or by the rate of progression from onset to baseline did not accord with the three prognostic groups.
CONCLUSIONS: Our results showed that the ALSFRS-R change in the run-in period or from onset to baseline is not useful for stratifying subsequent progression of functional decline in clinical trials.
After randomization, patients with thyroid hormone withdrawal therapy(i.e. Stop taking thyroid hormone for 14 days, and then monitor the level of thyroid-stimulating hormone every week). When TSH\>30mU/L, an ablative activity of 131I (30 mCi±1.5 mCi) was administered.
Children with Autism Spectrum Disorder (ASD) en NOT enrolled in the DENVER protocol. Same chronological age (1.5 years to 5 years of age) than children with ASD enrolled in the DENVER protocol. Those children will be recruited and tested at the Savoie Hospital Center (Chambery, France) and at the Grenoble University Hospital (Grenoble, France).
The invention discloses a traditional Chinese medicine used for treating type II diabetes. The medicine is composed of the components of, by weight: 10-12 parts of golden thread, 1-3 parts of red ginseng, 3-5 parts of American ginseng, 8-10 parts of asparagus cochinchinensis, 10-12 parts of mulberry leaf, 5-8 parts of fortune's eupatorium herb, 5-8 parts of greenish lily bulb, 10-12 parts of Asiatic plantain seed, 8-10 parts of aster striatus, 3-5 parts of panax notoginseng, 5-8 parts of Szechwan lovage rhizome, 10-12 parts of salvia miltiorrhiza, 10-12 parts of fiveleaf gynostemma herb or root, 5-8 parts of dried ginger, 5-8 parts of roughhaired holly root, and 10-12 parts of cherokee rose fruit. The traditional Chinese medicine provided by the invention can be used for treating type II diabetes. The traditional Chinese medicine provided by the invention has the functions of enhancing immunity, nourishing yin, generating body fluid, and clearing stomach-heat. The treatment effect against type II diabetes is good, and the blood sugar of a patient can be rapidly stabilized within a normal range. The traditional Chinese medicine has no toxic or side effect.
Scar tissue formation is a hallmark of wound repair in adults and can chronically affect tissue architecture and function. To understand the general phenomena, we sought to explore scar-driven imbalance in tissue homeostasis caused by a common, and standardized surgical procedure, the uterine scar due to cesarean surgery. Deep uterine scar is associated with a rapidly increasing condition in pregnant women, placenta accreta spectrum (PAS), characterized by aggressive trophoblast invasion into the uterus, frequently necessitating hysterectomy at parturition. We created a model of uterine scar, recapitulating PAS-like invasive phenotype, showing that scar matrix activates mechanosensitive ion channel, Piezo1, through glycolysis-fueled cellular contraction. Piezo1 activation increases intracellular calcium activity and Protein kinase C activation, leading to NF-κB nuclear translocation, and MafG stabilization. This inflammatory transformation of decidua leads to production of IL-8 and G-CSF, chemotactically recruiting invading trophoblasts towards scar, initiating PAS. Our study demonstrates aberrant mechanics of scar disturbs stroma-epithelia homeostasis in placentation, with implications in cancer dissemination.
A microbiocidal solution for in vivo and in vitro treatment of microbial infections containing an electrolyzed saline solution having a content of regulated amounts of ozone and active chlorine species. The ozone content is 5 to 100 mg/L (milligram per liter) and the chlorine species content is 5 to 300 parts per million (ppm). The active chlorine species comprises free chlorine, hypochlorous acid and the hypochlorite ion as measured by a chlorine selective electrode. The solution is prepared by subjecting a 1% or less saline to electrolysis under conditions sufficient to produce the active ingredients. The solution is used at an isotonic saline concentration and my be adjusted with hypertonic saline. The solution is used in vitro treatments of infected whole blood, blood cells or plasma to reduce contamination. The solution may also be administered to warm blooded animals, including humans by intravenous injection.
PCT No. PCT/JP92/01631 Sec. 371 Date Jun. 22, 1994 Sec. 102(e) Date Jun. 22, 1994 PCT Filed Dec. 15, 1992 PCT Pub. No. WO93/12769 PCT Pub. Date Jul. 8, 1993.A solid preparation soluble in the buccal cavity, which is composed of a sugar comprising lactose and/or mannitol and 0.1-1.2 w/w%, based on the sugar, of agar and an active ingredient and has a density of 400 to 1,000 mg/ml and such a strength as to withstand the handling in the manufacture thereof. It has such a sufficient practical solubility in the buccal cavity that even the aged or children having difficulty in swallowing a solid preparation, such as a tablet, can take it. It has an exceedingly high strength as compared with conventional open matrix structures and hence can withstand satisfactorily carrying and PTP packaging.
A previous study of 200,000 exome-sequenced UK Biobank participants investigating the association between rare coding variants and hyperlipidaemia had implicated four genes, LDLR, PCSK9, APOC3 and IFITM5, at exome-wide significance. In addition, a further 43 protein-coding genes were significant with an uncorrected p value of <0.001. Exome sequence data has become available for a further 270,000 participants and weighted burden analysis to test for association with hyperlipidaemia was carried out in this sample for the 47 genes highlighted by the previous study. There was no evidence to implicate IFITM5 but LDLR, PCSK9, APOC3, ANGPTL3, ABCG5 and NPC1L1 were all statistically significant after correction for multiple testing. These six genes were also all exome-wide significant in the combined sample of 470,000 participants. Variants impairing function of LDLR and ABCG5 were associated with increased risk whereas variants in the other genes were protective. Variant categories associated with large effect sizes are cumulatively very rare and the main benefit of this kind of study seems to be to throw light on the molecular mechanisms impacting hyperlipidaemia risk, hopefully supporting attempts to develop improved therapies.
The control group will not receive any treatment and continue their usual lifestyle. Balance, sensory measurement and skin blood flow will be taken at the beginning of the study, prior to the 5th treatment, and 1 week after the last intervention .
The invention relates to a medical appliance for heating human or animal tissue. The appliance comprises a first magnetic field device (1, 2) for generating a first magnetic field (M1) in the tissue to be heated, wherein the first magnetic field (M1) is a time-constant gradient field, and a second magnetic field device (5, 6) for generating a second magnetic field in the tissue to be heated, wherein the second magnetic field (M2) varies over time with a frequency. The first and second magnetic field devices (1,2; 5, 6) can be positioned relative to each other in such a way that the second magnetic field (M2) has, in the tissue to be heated, a magnetic field component perpendicular to the first magnetic field (M1), as a result of which particles (9), which have a magnetic moment (m) and which are introduced into the tissue to be heated during the operation of the appliance, are moved in rotary oscillations. The particles (9) in each case form an oscillatory system with a resonant frequency that depends on the magnitude of the first magnetic field (M1) at the site of the respective particle (9) and on the moment of inertia and the magnetic moment (m) of the respective particle (9). The appliance according to the invention further comprises a user interface (8), via which an area (A) of maximal heating can be specified in the tissue to be heated with particles introduced therein. The appliance is configured such that, depending on the magnetic moment (m) and the moment of inertia of the particles (9), the frequency of the second magnetic field and/or the magnitude of the first magnetic field (M1) are adjusted in such a way that the particles (9) in the area (A) specified via the user interface (8) oscillate substantially with the resonant frequency.
Nasal High-Flow oxygen delivery will be applied starting at airflow of minimum 20 Litre/minute. It will be titrated in 15Litre/minute increments to 35 Litre/minute and a maximum 50 Litre/minute as determined by patient comfort. O2 supplementation will be managed by the anesthesia and surgical health care team to maintain the oxygen saturation level in the blood between 92-95%. In the Nasal High-Flow group, when SPO2 is in the range of 92-95%, air will be given instead of oxygen for the 1st 3 nights and during the day, if required, till discharge, whichever is earlier.
Magnetic Resonance Force (MRF) is based on Magnetic Resonance Elastography which uses mechanical waves to quantitatively assess the viscoelastic properties of tumours and the shift in interstitial fluid pressure (or stiffness) of tissues.

It generates 3D images of applied deformation via low frequency acoustic waves within the tissue and provides a snapshot of the apparent stiffening of the tumour border zone. Growth induced stretch of the tumour not only increases stiffness but also alters the apparent change in stiffness due to additional loading. Magnetic Resonance Force (MRF) provides measures of MRE and macro-deformation at multiple load states therefore enabling estimation of tissue properties as well as the stress load relation. Since the stress load relation is related to tumour swelling and modifications, it can be directly linked to the tumour pre-strain and provides an indicator of the underlying interstitial tumour pressure. Using biomechanical models it is possible to directly translate the stress load relation into an estimate of IFP. The same approach also allows quantifying the active pull by cell traction forces (CTFs) coming from the tumour and exerted onto its surroundings. While that force is directed inwards, the force generated by the elevated interstitial fluid pressure (IFP) is directed outwards allowing separation of both effects from each other. These forces represent one of the biomarkers which we will quantify within the this project using MRF.
Patients receive PSC 833 IV continuously on days 1-3 and cytarabine, daunorubicin, and etoposide as in arm I. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of PSC 833 IV continuously on days 1 and 2 and cytarabine, daunorubicin, and etoposide as in arm I.
An evaluation method of sleep quality and a computing apparatus related to sleep quality are provided. In the evaluation method, sensing data is obtained. The sensing data is generated based on radar echo. The sensing data is transformed into feature data. The feature data includes statistics of multiple feature points on the waveform of the radar echo. The sleep quality information is determined according to the feature data. The sleep quality information is related to whether the sleep quality is good or bad. Accordingly, sleep quality could be evaluated through non-touch sensing.
PURPOSE: A composition containing natural plant extract for preventing or treating inflammatory diseases or asthma is provided to suppress inflammation and asthma without cytotoxicity. CONSTITUTION: A composition for preventing or treating inflammatory diseases contains Lilium lancifolium syn. L. tigrinum extract or fraction thereof as an active ingredient. A composition for preventing or treating asthma contains the Lilium lancifolium syn. L. tigrinum extract or fraction thereof as an active ingredient. A method for manufacturing Lilium lancifolium syn. L. tigrinum extract comprises: a step of pulverizing dried Lilium lancifolium syn. L. tigrinum and adding methanol; a step of suspending and adding butanol; a step of filtering the butanol extract; and a step of decompressing the extract. A method for preparing the fraction of Lilium lancifolium syn. L. tigrinum extract comprises: a step of adsorbing the Lilium lancifolium syn. L. tigrinum extract on a silica gel; and a step of enhancing concentration gradient of choloform-methnaol mixture solvent on the silica gel.
PROBLEM TO BE SOLVED: To prepare a skin liniment having prevention of roughed skin and large recovering activities thereof by combining activities of silk protein for promoting treatment of wound and activities for promoting recovery of alginic acid salt. SOLUTION: This skin liniment is obtained, for example, by adding 0.050-5 g silk fibroin and 0.050-5 g sodium alginate to 1000 ml water and sufficiently stirring the water with added materials. The solution is gelled by the action of the silk fibroin and sodium alginate (containing calcium as a part) and becomes a form suitable for coating on the skin. By coating the skin liniment, the roughened skin by a long term contact with water or a detergent is recovered to the original fresh skin rapidly. In the case of comparatively short term operation or the case capable of being coated therewith, the skin roughening is efficiently prevented by previously coating the skin liniment depending on this invention on the skin before the operation. A preservative (for example, <=30 mg sodium benzoate) is optionally admixed therewith in the practical use.
PURPOSE:To discriminate easily the presence or absence of agglutination and to make possible a reagent for diagnosis having an excellent shelf life by compounding nicotinic acid amide with a water dispersion of water dispersion type high-molecular polymer particles immobilized with an immunologically active material so as to co-exist therein. CONSTITUTION:The water dispersion type high-molecular polymer particles are dispersed into a buffer soln. such as glycine buffer soln., phosphoric acid buffer soln. or boric acid buffer soln. having suitable pH and concn. so as to prevent the inactivation of the immobilized immunologically active material and the nicotinic acid amide is compounded as an additive for suppressing the non-specific agglutination of the particles with the water dispersion of such polymer particles. Since the non-specific agglutination of the polymer particles is thoroughly prevented, the quick discrimination is possible without the dilution of serum with a buffer soln. or without inactivation treatment. The reagent for diagnosis is easy to mix uniformly with the serum. The discrimination of the presence or absence is thus made easy and the shelf life thereof is remarkably improved.
Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
This invention relates to amino acid sequences from within a consensus peptide of the formula: VEKNITVTASVDPTIDLLQADGSALPSAVALTYSPA (Seq. #1). Eight mer peptides from within the consensus peptide were tested against an antibody raised to the consensus peptide. Studies relating to antibody raised to denatured proteins from the natural organisms producing the family of proteins were also useful and showed particular value of some sequences. A sequence of the formula ASVDPTIDLLQA (Seq. #2) was identified thereby. An enlarged sequence of the formula TVTASVDPTIDLLQAD (Seq. #3) is also especially interesting as are intermediate sequences such as sequences VTASVDPTIDLLQAD (Seq. #4), TASVDPTIDLLQAD (Seq. #5), and TASVDPTIDLLQA (Seq. #6) as being binding sites for antibodies raised to the denatured proteins.
Plastic pollution pervades both marine and terrestrial ecosystems, fragmenting over time into microplastics (MPs) and nano-plastics (NPs). These particles infiltrate organisms via ingestion, inhalation, and dermal absorption, predominantly through the trophic interactions. This review elucidated the impacts of MPs/NPs on the reproductive viability of various species. MPs/NPs lead to reduced reproduction rates, abnormal larval development and increased mortality in aquatic invertebrates. Microplastics cause hormone secretion disorders and gonadal tissue damage in fish. In addition, the fertilization rate of eggs is reduced, and the larval deformity rate and mortality rate are increased. Male mammals exposed to MPs/NPs exhibit testicular anomalies, compromised sperm health, endocrine disturbances, oxidative stress, inflammation, and granulocyte apoptosis. In female mammals, including humans, exposure culminates in ovarian and uterine deformities, endocrine imbalances, oxidative stress, inflammation, granulosa cell apoptosis, and tissue fibrogenesis. Rodent offspring exposed to MPs experience increased mortality rates, while survivors display metabolic perturbations, reproductive anomalies, and weakened immunity. These challenges are intrinsically linked to the transgenerational conveyance of MPs. The ubiquity of MPs/NPs threatens biodiversity and, crucially, jeopardizes human reproductive health. The current findings underscore the exigency for comprehensive research and proactive interventions to ameliorate the implications of these pollutants.
This study will be a randomized clinical trial that will investigate the effectiveness of silver spike point therapy and manual therapy in subjects with pregnancy-related pelvic girdle pain. Subjects with pregnancy-related pelvic girdle pain meeting the predetermined inclusion \& exclusion criteria will be divided into two groups using the lottery method. Pre-assessment will be done using NPRS and PGPQ as subjective measurements and PSFS as objective measurements. Subjects in one group will be treated with silver spike point therapy and manual therapy, the other will be treated with manual therapy only. Each subject will receive 10 treatment sessions, with 05 treatment sessions per week. Post-treatment reading for NPRS, PGPQ, and PSFS will be recorded after the end of the 10th treatment session. Recorded values will be analyzed for any significant difference between pre and post-treatment values SPSS 21.